3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
16
Uterine Cervical Neoplasms
5
Stomach Neoplasms
5
Lung Neoplasms
5
Carcinoma, Transitional Cell
5
Carcinoma, Hepatocellular
5
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Oropharyngeal Neoplasms
4
Esophageal Neoplasms
4
Cholangiocarcinoma
4
Urinary Bladder Neoplasms
3
Thyroid Neoplasms
3
Neuroendocrine Tumors
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Lymphoma, Large B-Cell, Diffuse
3
Anus Neoplasms
3
Testicular Neoplasms
2
Solid Tumor
2
Pheochromocytoma
2
Paraganglioma
2
Pancreatic Neoplasms
2
Neoplasms
2
Mouth Neoplasms
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Laryngeal Neoplasms
2
Interventions
Nivolumab
6
atezolizumab
5
Cisplatin
5
Ipilimumab
4
Carboplatin
4
Etoposide
3
pembrolizumab
2
gallium Ga 68 dotatate
2
dostarlimab
2
Temozolomide
2
Positron Emission Tomography Computed Tomography
2
Paclitaxel
2
Magnetic Resonance Imaging
2
Irinotecan
2
Immunoglobulin G
2
IFL protocol
2
Disulfides
2
zimberelimab
1
tivozanib
1
repotrectinib
1
niraparib
1
lutetium Lu 177 dotatate
1
lenvatinib
1
iadademstat
1
durvalumab
1
cabozantinib
1
budigalimab
1
belinostat
1
Topotecan
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Neuroendocrine
×
Fluorodeoxyglucose F18
×
1 year
×
Clear all
No trials found.